| Ytd | -29.53% | |
| 1y | -40.36% |
| Open | 12.37 | Prev Close | 12.22 | Low | 12.14 | High | 12.37 | Mkt Cap | 173.09M |
| Vol | 29.11K | Avg Vol | 757.23K | EPS | -10.14 | P/E | -1.21 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 19.06 | 200-d Avg | 21.19 | 1yr Est | 0.00 |
EVMN News
Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chroni
Oversold health care stocks: EVMN, NNNN, NAUT. RSI <30 shows they may be undervalued. EVMN drop
Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this cre
Evommune's CEO and CSO sold shares on June 22, 2026, under Rule 10b5-1 plans adopted months earlier
Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the compan
Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and lowers
Wall Street analysts changed outlook on top names, including Alphine Income Property Trust, AAR Corp
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday
Read Also: Evommune Stock Cools Off After Big Rally On Successful Eczema Trial
Evommune said EVO756 failed to meet the primary endpoint in a Phase 2b CSU trial, ending development
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 poi
US stocks higher, Nasdaq up 1%. Dow up 0.60%, Nasdaq up 1.34%, S&P 500 up 0.82%. Communication s
Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechn
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommu
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa
Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist i
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa
Capricorn Fund Managers Ltd acquired a new stake in Evommune, Inc. (NYSE: EVMN) in the fourth quarte
Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S
Shares of Evommune, Inc. (NYSE: EVMN - Get Free Report) have been assigned an average rating of "Mod
Clinical-stage biotech Evommune is seen as a potential buyout candidate. Its shares are up more than
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa
Evommune, Inc. (NYSE: EVMN - Get Free Report) has earned a consensus rating of "Moderate Buy" from t
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (“Evommune” or the “Company”) (NYSE: E
Evommune, Inc. (NASDAQ: EVMN) shares are trading lower on Thursday on profit-taking after the stock
The 70-patient trial was designed to evaluate the safety and efficacy of intravenous dosing of 5mg/k
IPO stock Evommune roughly doubled Tuesday on positive results for its intravenously infused eczema
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommu
Shares of Evommune, Inc. (NYSE: EVMN - Get Free Report) have been assigned an average recommendation
